SYD-4228 by Byondis for Follicular Lymphoma: Likelihood of Approval

SYD-4228 is under clinical development by Byondis and currently in Phase I for Follicular Lymphoma.

Bausch Health’s Salix initiates first awareness day for opioid-induced constipation

Salix Pharmaceuticals is partnering with two advocacy groups to establish a first-ever opioid-induced constipation (OIC) awareness day to help dispel the stigma and silence around

December 6, 2023

Opinion | In the Face of Misogyny in Medicine, Be a Better Person

Lee is a psychiatry resident. When a patient discloses an experience of harassment, abuse, or assault, our first response as physicians, we are taught, should

February 7, 2024

Merck touts topline PhIII Keytruda data in pre-surgery breast cancer treatment

Merck’s blockbuster anti-PD-1 therapy Keytruda is inching its way toward another potential indication, this time a chemotherapy combo pre-surgery in patients with high-risk, early-stage ER+/HER2-

July 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.